Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF V600 Mutation”

92 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 92 results

Early research (Phase 1)Ended earlyNCT01611675
What this trial is testing

Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma

Who this might be right for
Melanoma
Massachusetts General Hospital 3
Early research (Phase 1)Study completedNCT02608034
What this trial is testing

Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

Who this might be right for
Metastatic Melanoma, BRAF V600 Mutation Positive
Genentech, Inc. 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT02231775
What this trial is testing

Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

Who this might be right for
Stage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7
M.D. Anderson Cancer Center 58
Testing effectiveness (Phase 2)Ended earlyNCT02052193
What this trial is testing

Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study

Who this might be right for
Metastatic Melanoma (Carrying BRAF V600 Mutation)
University Hospital Tuebingen 8
Testing effectiveness (Phase 2)UnknownNCT05528406
What this trial is testing

A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation

Who this might be right for
Solid Tumor
Shanghai Henlius Biotech 30
Testing effectiveness (Phase 2)Study completedNCT01677741
What this trial is testing

Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

Who this might be right for
Neoplasms, Brain
Novartis Pharmaceuticals 85
Testing effectiveness (Phase 2)Study completedNCT03915951
What this trial is testing

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Pfizer 98
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05275374
What this trial is testing

XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation

Who this might be right for
CancerBRAF V600 MutationMelanoma+3 more
Xynomic Pharmaceuticals, Inc. 221
Not applicableLooking for participantsNCT06749015
What this trial is testing

A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)

Who this might be right for
Metastatic Colorectal CancerBRAF V600 Mutation
Fudan University 100
Testing effectiveness (Phase 2)Study completedNCT02296112
What this trial is testing

Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations

Who this might be right for
Recurrent MelanomaStage IIIB MelanomaStage IIIC Melanoma+1 more
Vanderbilt-Ingram Cancer Center 9
Testing effectiveness (Phase 2)Looking for participantsNCT07110246
What this trial is testing

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

Who this might be right for
BRAF V600 MutationLow-grade GliomaLow Grade Glioma of Brain+1 more
University of California, San Francisco 96
Testing effectiveness (Phase 2)UnknownNCT05102292
What this trial is testing

The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation

Who this might be right for
Anaplastic Thyroid CancerATC
Shanghai Henlius Biotech 25
Testing effectiveness (Phase 2)Study completedNCT02083354
What this trial is testing

Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

Who this might be right for
CancerMelanoma
Novartis Pharmaceuticals 77
Early research (Phase 1)Study completedNCT01436656
What this trial is testing

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Who this might be right for
Melanoma and Metastatic Colorectal Cancer
Pfizer 107
Early research (Phase 1)Ended earlyNCT04190628
What this trial is testing

Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorBRAF V600 Mutation
ABM Therapeutics Corporation 53
Not applicableStudy completedNCT01804140
What this trial is testing

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

Who this might be right for
Multiple Myeloma, Neoplasms
Genentech, Inc. 662
Not applicableStudy completedNCT03139513
What this trial is testing

Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])

Who this might be right for
Melanoma
Hoffmann-La Roche 200
Early research (Phase 1)Study completedNCT04462471
What this trial is testing

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Who this might be right for
Thyroid CarcinomaThyroid CancerThyroid Cancer, Follicular+3 more
Memorial Sloan Kettering Cancer Center 8
Early research (Phase 1)Ended earlyNCT05501912
What this trial is testing

ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorBRAF V600 Mutation
ABM Therapeutics Shanghai Company Limited 20
Not applicableNo Longer AvailableNCT04544202
What this trial is testing

Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection

Who this might be right for
MelanomaAdjuvant
Novartis Pharmaceuticals
Load More Results